Amgen has appointed Anna Richo to the post of senior vice president, worldwide compliance. Richo will take responsibility for ensuring Amgen meets the requirments of drug industry regulators worldwide.. Richo has worked for Amgen since 2003, most recently holding the post of vice president, Law. Prior to this she spent 12 years at Baxter Healthcare in various roles in the field of law. Alex Chanin has been promoted to the post of chief operating officer at Vital Signs, a manufacturer of primarily single-use medical products. Chanin has served as executive vice president and chief information officer for Vital Signs since January 2004 and has over 20 years in the pharmaceutical and medical device industries. Minster Pharmaceuticals has appointed Joseph Lofft as a US consultant. Lofft has more than 20 years experience in product development, including overseeing the launch and growth of Johnson & Johnson's migraine treatment Topamax (topiramate). Lofft has been involved with pharmaceutical product development for more than 20 years. Minster believes this, and in particular Lofft's knowledge of the migraine prevention market will help the company advance its clinical studies of tonabersat, a migraine prevention compound. Dr Mahnaz Asgharnejad has been appointed to the post of vice president of clinical development at CeNeRx BioPharma, a biopharmaceutical company developing treatments for central nervous system (CNS) diseases. In this capacity Asgharnejad will play a central role in expanding CeNeRx's clinical development capabilities and advancing the clinical trials of CeNeRx's investigational drugs. Asgharnejad has spent more than two decades at GlaxoSmithKline (GSK) and has managed projects at all phases of development, including successful new product submissions to the FDA. Michael Faughnan has been named as business development director of Eden Biodesign US subsidiary, Eden Biodesign, Inc. In this capacity Faughnan will be responsible for North American business development activities. Faughnan has over 14 years of experience taking biopharmaceutical products through clinical development to commercial launch. Most recently he held a post at contract manufacturer, Cytovance Biologics and has also worked for Irvine Scientific and Woodside. US-based biotechnology company AngioGenex has appointed William Garland as its new CEO. Garland has previously worked at Hoffmann La Roche and has directed research and development programs for early stage biotech companies including Centaur Pharmaceuticals, Atairgin Technologies, Lpath Therapeutics and Tosk. Medicure, a cardiovascular-focused biopharmaceutical company, has appointed Dwayne Henley as its new chief financial officer.
